Total Payments
$7,181
2024 Payments
$493.58
Companies
45
Transactions
393
Medicare Patients
7,247
Medicare Billing
$1.9M
Payment Breakdown by Category
Food & Beverage$5,816 (81.0%)
Travel$1,349 (18.8%)
Education$16.45 (0.2%)
Gifts$0.01 (0.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,816 | 380 | 81.0% |
| Travel and Lodging | $1,349 | 3 | 18.8% |
| Education | $16.45 | 9 | 0.2% |
| Gift | $0.01 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $1,872 | 12 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $454.55 | 41 | $0 (2024) |
| PFIZER INC. | $363.59 | 50 | $0 (2019) |
| Merz North America, Inc. | $294.67 | 20 | $0 (2019) |
| ABBVIE INC. | $291.57 | 14 | $0 (2024) |
| SCILEX PHARMACEUTICALS INC. | $290.41 | 14 | $0 (2024) |
| Allergan, Inc. | $274.67 | 18 | $0 (2022) |
| Merz Pharmaceuticals, LLC | $239.90 | 8 | $0 (2024) |
| Pernix Therapeutics Holdings, Inc. | $213.51 | 18 | $0 (2019) |
| Abbott Laboratories | $199.28 | 15 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $493.58 | 19 | ABBVIE INC. ($127.67) |
| 2023 | $338.49 | 15 | AbbVie Inc. ($88.18) |
| 2022 | $687.07 | 29 | Scilex Pharmaceuticals Inc. ($137.84) |
| 2021 | $442.46 | 30 | Allergan, Inc. ($76.97) |
| 2019 | $893.91 | 57 | Merz North America, Inc. ($90.80) |
| 2018 | $2,865 | 103 | BOSTON SCIENTIFIC CORPORATION ($1,778) |
| 2017 | $1,461 | 140 | Collegium Pharmaceutical, Inc. ($189.76) |
All Payment Transactions
393 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: Neurology | ||||||
| 12/19/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $22.41 | General |
| Category: Opioid Analgesic | ||||||
| 12/12/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $44.26 | General |
| Category: Musculoskeletal | ||||||
| 11/14/2024 | SPR Therapeutics, Inc | SPRINT PNS System (Device) | Food and Beverage | Cash or cash equivalent | $35.29 | General |
| Category: Pain management | ||||||
| 08/29/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $27.56 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $17.19 | General |
| Category: Opioid Analgesic | ||||||
| 08/01/2024 | SI-BONE, INC. | — | Food and Beverage | Cash or cash equivalent | $26.96 | General |
| 06/13/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $28.87 | General |
| Category: NEUROSCIENCE | ||||||
| 05/02/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $33.51 | General |
| Category: Musculoskeletal | ||||||
| 04/26/2024 | Nevro Corp. | Senza (Device) | Food and Beverage | In-kind items and services | $33.51 | General |
| Category: Spinal Cord Stimulator | ||||||
| 04/18/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Opioid Analgesic | ||||||
| 04/11/2024 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $24.13 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 04/04/2024 | ABBVIE INC. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: NEUROSCIENCE | ||||||
| 04/03/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $26.75 | General |
| Category: NEUROSCIENCE | ||||||
| 03/01/2024 | Fidia Pharma USA Inc. | HYMOVIS (Device) | Food and Beverage | In-kind items and services | $23.53 | General |
| Category: OSTEOARTHRITIS | ||||||
| 02/15/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Neurology | ||||||
| 02/08/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 01/11/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $21.14 | General |
| Category: Neurology | ||||||
| 01/04/2024 | SCILEX PHARMACEUTICALS INC. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $24.33 | General |
| Category: Analgesic | ||||||
| 12/15/2023 | AbbVie Inc. | UBRELVY (Drug), BOTOX | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: NEUROSCIENCE | ||||||
| 11/09/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: PAIN MANAGEMENT | ||||||
| 11/02/2023 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: Neurology | ||||||
| 09/21/2023 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: Musculoskeletal | ||||||
| 08/31/2023 | AbbVie Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $24.31 | General |
| Category: Analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 1,873 | 8,377 | $1.5M | $412,607 |
| 2022 | 25 | 1,763 | 8,941 | $1.7M | $493,556 |
| 2021 | 24 | 1,807 | 9,851 | $1.7M | $516,763 |
| 2020 | 25 | 1,804 | 9,189 | $1.5M | $466,800 |
Total Patients
7,247
Total Services
36,358
Medicare Billing
$1.9M
Procedure Codes
100
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 235 | 1,738 | $416,388 | $144,756 | 34.8% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 184 | 325 | $131,974 | $63,135 | 47.8% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 70 | 78 | $209,223 | $37,090 | 17.7% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 70 | 78 | $107,374 | $20,372 | 19.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 120 | 261 | $42,998 | $15,469 | 36.0% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 151 | 232 | $43,848 | $14,129 | 32.2% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2023 | 58 | 95 | $75,716 | $13,691 | 18.1% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 51 | 67 | $57,611 | $13,068 | 22.7% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 34 | 67 | $70,057 | $12,385 | 17.7% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 73 | 80 | $28,320 | $12,277 | 43.4% |
| 20611 | Aspiration and/or injection of fluid large joint using ultrasound guidance | Office | 2023 | 73 | 152 | $48,647 | $11,944 | 24.6% |
| 64633 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 21 | 23 | $55,650 | $10,493 | 18.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 60 | 60 | $21,235 | $6,672 | 31.4% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 34 | 67 | $35,014 | $6,529 | 18.6% |
| 64634 | Destruction of upper or middle spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 21 | 23 | $25,270 | $6,183 | 24.5% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2023 | 15 | 23 | $17,981 | $4,247 | 23.6% |
| 64484 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | Office | 2023 | 36 | 48 | $16,368 | $4,015 | 24.5% |
| 64490 | Injection of upper or middle spine facet joint using imaging guidance, single level | Office | 2023 | 14 | 21 | $22,213 | $3,876 | 17.5% |
| 64445 | Injection of anesthetic agent and/or steroid into lower back and leg nerve (sciatic nerve) | Office | 2023 | 20 | 26 | $11,338 | $2,897 | 25.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 211 | 2,981 | $44,715 | $2,378 | 5.3% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 37 | 60 | $9,415 | $2,376 | 25.2% |
| 64491 | Injection of upper or middle spine facet joint using imaging guidance, second level | Office | 2023 | 14 | 21 | $11,449 | $2,064 | 18.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 105 | 161 | $4,830 | $1,621 | 33.6% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 17 | 23 | $3,859 | $582.25 | 15.1% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 105 | 641 | $724.33 | $261.46 | 36.1% |
About Dr. Ed Atty, MD
Dr. Ed Atty, MD is a Rehabilitation Practitioner healthcare provider based in Flint, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144260332.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ed Atty, MD has received a total of $7,181 in payments from pharmaceutical and medical device companies, with $493.58 received in 2024. These payments were reported across 393 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($5,816).
As a Medicare-enrolled provider, Atty has provided services to 7,247 Medicare beneficiaries, totaling 36,358 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Ad
Practice Information
- Specialty Rehabilitation Practitioner
- Other Specialties Specialist, Physical Medicine & Rehabilitation
- Location Flint, MI
- Active Since 06/07/2006
- Last Updated 11/12/2014
- Taxonomy Code 225400000X
- Entity Type Individual
- NPI Number 1144260332
Products in Payments
- SPECTRA WAVEWRITER (Device) $1,778
- LYRICA (Drug) $336.54
- BOTOX (Biological) $325.59
- Xeomin (Biological) $306.51
- XEOMIN (Biological) $228.06
- ZOHYDRO ER (Drug) $200.87
- ZTLido (Drug) $175.54
- Xtampza ER (Drug) $167.94
- Amitiza (Drug) $154.85
- XTAMPZA (Drug) $153.55
- RELISTOR (Drug) $129.08
- Zilretta (Drug) $118.28
- Omnia (Device) $113.87
- Movantik (Drug) $109.63
- Nucynta (Drug) $105.77
- Dysport (Drug) $103.69
- DRG IPGs (Device) $98.59
- NURTEC ODT (Drug) $98.59
- Lucemyra/Lofexidine (Drug) $97.49
- BOTOX THERAPEUTIC (Biological) $94.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.